Avanos Medical Stock Price, News & Analysis

Avanos Medical (NYSE: AVNS) has announced the appointment of Michael Greiner as Chief Transformation Officer, alongside his role as CFO, and Kerr Holbrook as Senior Vice President and Chief Commercial Officer. This leadership shift aims to enhance the company's strategic focus and optimize financial performance over the next three years. The transformation plan centers on four priorities: optimizing the commercial organization, transforming the product portfolio, implementing cost management initiatives, and disciplined capital deployment. The new structure aims to accelerate sales and improve market impact.

Avanos Medical (NYSE: AVNS) will be represented by CEO Joe Woody at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on January 11, 2023, at approximately 4:30 p.m., PST. A webcast of the presentation will be accessible on the Investors section of the Avanos Medical website, and it will be archived for future viewing. Avanos is dedicated to advancing healthcare needs by providing innovative medical device solutions aimed at enhancing patients' quality of life.

Avanos Medical has appointed Sudhakar Varshney as the new senior vice president of global supply chain & procurement, effective immediately. Varshney brings over 20 years of leadership experience in various sectors including medical devices and automotive, having previously served at Antylia Scientific and other notable companies. His role entails leading a team of over 2,500 employees to enhance the company’s supply chain operations amidst ongoing global challenges. CEO Joe Woody expressed confidence in Varshney's ability to drive essential process improvements for the company’s growth.

Avanos Medical, based in Alpharetta, Georgia, will present at the Stifel 2022 Healthcare Conference on November 15 at 3:35 p.m. ET. CEO Joe Woody and CFO Michael Greiner will lead the presentation. The conference will be accessible via a webcast on the Avanos Medical website's investors section, with an archive for later viewing. Avanos Medical focuses on developing innovative medical devices aimed at improving patient quality of life and reducing opioid use. The company operates in over 90 countries.

Avanos Medical reported third quarter 2022 financial results with net sales of $202 million, marking a 10% increase year-over-year. Gross margin improved to 54%, up from 49% in the prior year. The company achieved a net income of $16 million compared to a $35 million loss last year, and adjusted earnings per share rose to $0.38. Free cash flow reached $23 million. The company reaffirms its 2022 guidance, projecting net sales between $815 million and $835 million despite ongoing supply chain challenges.

Avanos Medical (NYSE: AVNS) will host a conference call on November 2, 2022, at 9 a.m. ET to discuss its third-quarter financial results and business highlights. A news release will precede the call, detailing the company's performance. The call will be led by CEO Joe Woody and CFO Michael Greiner. Interested parties can join by dialing 877-240-5772 within the U.S. The replay will be available following the event for one week. Avanos focuses on providing innovative medical solutions to improve patient recovery.

Avanos Medical (NYSE: AVNS) announced that CEO Joe Woody and CFO Michael Greiner will participate in a fireside chat during the Morgan Stanley Global Healthcare Conference on September 14, 2022, at around 1:30 p.m. ET. A webcast of their presentation will be available on the Investors section of Avanos Medical's website and will be archived there for future reference. Avanos Medical focuses on delivering innovative medical device solutions that enhance patients' quality of life.

Avanos Medical, Inc. (NYSE: AVNS) reported its Q2 2022 results, with net sales of $203 million, a 9% increase year-over-year. Gross margin improved significantly, reaching 57% compared to 46% a year ago. However, net income dropped to $11 million from $38 million in the prior year. The company generated free cash flow of $23 million, up from $10 million last year. Despite supply chain challenges, Avanos expects full-year sales between $815 million and $835 million, projecting adjusted diluted EPS between $1.45 and $1.65.

Avanos Medical, Inc. (NYSE: AVNS) will host a conference call on August 9, 2022, at 9 a.m. ET, to discuss its second-quarter financial results and business highlights. The company will release its financial results before the market opens on the same day. The call will be led by CEO Joe Woody and CFO Michael Greiner. Interested parties can join the call by dialing 877-240-5772 within the U.S. A replay will be available starting August 10 at noon ET. Avanos focuses on innovative medical devices aimed at improving recovery and reducing opioid use.